Effect of Ivermectin on Time to Resolution of Symptoms
Link to FLCCC ALLIANCE I-RECOVER POST-VACCINE TREATMENT PROTOCOL.
"Major public health authorities do not recognize post-COVID-vaccine injuries; and there is no specific ICD classification code for this disease. However, while no official definition exists, a temporal correlation between receiving a COVID-19 vaccine and beginning or worsening of a patient's clinical manifestations is sufficient to diagnose as a COVID-19 vaccine-induced injury, when the symptoms are unexplained by other concurrent causes.
Early treatment is essential; it is likely that the response to treatment will be attenuated when treatment is delayed."
Although Ivermectin has not been authorised in many Western countries against COVID-19, many countries permit its use against parasite diseases.
All reports and text in this website are supported by links to their sources, while any personal comments are in red in italics.
Please click on the bold dark blue text which are links which will take you to the source data, so that you can evaluate its veracity yourself.
This web-page shows reports where ivermectin has had great success in reducing illnes, hospitalisation and death for patients with COVID-19.
Further below see possible reasons for resistance to administering ivermectin.
There are also pages on this website about other promising drugs and vitamins that may treat Covid-19.
For an excellent article that anyone can understand on
ivermectin by Sameena Amien and FAIRLADY here is a link to the pdf.
This is an absolutely excellent short documentary (just 13 minutes) on Ivermectin and what THEY did to keep it from you and me.
Please forward it to anyone that has ever mentioned "horse" in the same sentence as Ivermectin.
Reports of Ivermectin's success against Covid-19
Dr. Mark Trozzi on how well Ivermectin works, and other fascinating information on Ivermectin.
Journal Says Ivermectin Study Met Standard for 'Credible Science'. Medscape Tuesday, October 18, 2022.
A journal editor is defending his decision to publish a new paper showing that ivermectin can prevent Covid-19, despite more than a dozen retractions of such papers from the literature. The article, "Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects, " appeared in Cureus August 31 2022.
Conclusion: In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection,
hospitalization, and mortality rates. Published: January 15, 2022.
The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001).
When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate
(44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables,
reduction in hospitalization rate was 67% (RR, 0.33; 95% CI, 023-0.66; p < 0.0001).
Note that this study was specifically for ivermectin as a prophylactic,
as usage was discontinued when subjects tested positive to COVID-19
Ivermectin saves India - Jun 14, 2021.
Those Indian states that adopted more aggressive Ivermectin policies saw their cases fall far more than 80%, states like Uttar Pradesh - down 98% - 37,944 to 596,
Uttarakhand - down 97% - 9642 to 287 and Goa - down 90% - 4195 to 423. Delhi saw a 99% drop - 28,395 to 238.
Tamil Nadu, which publicly banned Ivermectin, saw their cases rise to the highest in India, and they continued setting state records as at May 21, 2021,
when they peaked at 36,184. By contrast, Tamil Nadu's deaths rose ten-fold from April 20 to May 27. On June 9, Tamil Nadu's COVID-19 deaths remained the second highest in India at 405,
while the states that chose Ivermectin were all dramatically better.
The bottom line is that Ivermectin works, and it works extraordinarily well.
Ivermectin is effective for COVID-19: real-time meta-analysis of 99 studies and growing with 137,255 patients
in 24 Countries as at 9 October 2023 with more appearing regularly.
As at 83%, 63% and 39% improvement for prophylaxis, early treatment and late treatment.
Random effects meta-analysis for early treatment and pooled effects shows a reduction of 83%, RR 0.17 [0.11-0.28].
Prophylactic use shows a reduction of 83%, RR 0.11 [0.05-0.23].
Mortality results show 78% lower mortality, RR 0.22 [0.12-0.41] for all treatment delays, and 86% lower, RR 0.14 [0.03-0.62] for early treatment.
100% of the 24 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 72%, RR 0.28 [0.17-0.47].
The probability that an ineffective treatment generated results as positive as the 60 studies to date is estimated to be 1 in 9 trillion (p = 0.00000000000009).
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally
https://www.medpagetoday.com/special-reports/exclusives/93485?xid=nl_popmed_2021-07-09&eun=g1631938d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=PopMedicine_070921&utm_term=NL_Gen_Int_PopMedicine_Active to treat SARS-CoV-2 infection by Andrew Hill, published 6 July 2021 in Open Forum Infectious Diseases.
In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality, with favorable clinical recovery and reduced hospitalization. As for moderate disease, they reported a 70% improvement in survival with ivermectin. Use of ivermectin was also associated with a reduction in time to recovery of 1.58 days compared with controls with a shorter duration of hospitalization.
Click here for Prof Eli Schwartz pre-presentation of the Sheba Ivermectin Project, claimed to be the "first world, randomised, double-blind placebo-control (RDBPC) trial" now published in MedRxiv and in Israel - Sheba Ivermectin Project - previewed February 2021. Sheba Medical Center is the largest hospital in Israel, which Newsweek ranked it as the 9th-best hospital in the world. The objectives were to evaluate the reduction in viral shedding among mild to moderate Covid-19 patients and to evaluate the effect of preventing the progression of clinical disease.
Prof Schartz shows figures that prove that ivermectin was successful in both instances.
Dr Andrew Hill from Liverpool recently presented his meta-analysis data on the use of ivermectin in Covid-19, with a total of 7,100 patients from 53 available clinical trials. Many of these trials were the same as those in the more current above paragraph.
This meta-analysis investigated ivermectin in 18 randomised clinical trials (2282 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent. In six randomised trials of moderate or severe infection, there was a 75% reduction in mortality.
"Across these six trials in 1255 patients, there were 14/658 (2.1%) deaths in the ivermectin arms, versus 57/597 (9.5%) deaths in the control arms. A combined analysis using inverse variance weighting ivermectin showed a 75% improvement in survival (RR 0.25 [95%CI 0.12-0.52]; p=0.0002, Figure 2). Heterogeneity was moderate, I 2 = 34%."
FLCCC Alliance Response to the NIH Guideline Committee Recommendation on Ivermectin use
in COVID-19 dated January 14th, 2021
Last month, Dr Kory and his team testified before the U.S. Senate Homeland Security Committee in favour of authorising ivermectin, a Nobel Prize-winning antiparasitic agent,
for early treatment of the novel coronavirus. In his impassioned presentation, Dr Kory explained that Ivermectin "basically obliterates transmission of this virus" with "miraculous effectiveness."
Ivermectin has been the subject of dozens of studies and anecdotal success stories since it was found to reduce COVID-19 in a laboratory last June.
"I've been treating COVID pretty much every single day since the onset," Kory said at the December hearing. "When I say 'miracle', I do not use that term lightly.
Mountains of data that has emerged in the last three months."
Such data emanates from places like India, the second most populated nation in the world, which embraced the treatment protocol advanced by FLCCC and has watched its
case and fatalities rate drop-in "steep decline." As of the end of June 2021, India has 285 Covid-9 deaths per million, while the USA has 1,860 per million, about six times the mortality.
Other examples come from Bangladesh, Peru, Argentina, Brazil and several other South American countries, all of which have demonstrated the effectiveness of ivermectin.
Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC
FLCCC Alliance press conference from Houston, Texas -5 December 2021. Includes dosages and
explains that giving a placebo with the observational evidence is unethical.
FLCCC Weekly Updates & Special Events
The National Institutes of Health (NIH)
has upgraded their recommendation for ivermectin, making it an option for use in treating COVID-19 - Jan 19, 2021.
The result comes one week after Dr Paul Marik and Dr Pierre Kory - founding members of the FLCCC, along with Dr Andrew Hill, researcher and consultant to the World Health Organization (WHO),
presented their data before the NIH Treatment Guidelines Panel.
"We See That This Works" "People are dying," Dr Marik said during a phone interview. "We treat patients at the bedside. We don't have the ivory tower syndrome where you tell people what to do though you have no idea what you're doing." "I could not have a patient admitted to my care and give placebo knowing what I know about ivermectin." Steven Joffe, MD, MPH, a medical ethicist at the University of Pennsylvania, said he doesn't believe clinicians "should be lowering our standards of evidence because we're in a pandemic."
Group members, mostly critical care physicians, don't see a need for more data and argue it would be unethical to give a placebo to patients given ivermectin's established safety.
But that's raising more than a few eyebrows among others in the field.
Marik said the group adapted the protocol for COVID-19, using a potent steroid and adding an anticoagulant, along with other elements. The new name was MATH+, for methylprednisolone,
ascorbic acid, thiamine, and heparin, plus a statin, zinc, vitamin D, famotidine, melatonin, and magnesium.
Video by Dr Chris Martenson - Tuesday, December 8, 2020, when he goes through the ivermectin studies. Warning! This video was banned by YouTube.
Not Using Ivermectin, One Year In,
Is Unethical And Immoral Incomprehensibly, the people we should trust to make the call on ivermectin are paralyzed by indecision and cowardice.
For eight months, while hundreds of thousands died, the National Institutes of Health advised against using ivermectin except in clinical trials. Last week,
NIH brushed aside evidence of efficacy in several thousand patients who took ivermectin and decreed there was "insufficient data to recommend either for or against."
80-year-old Buffalo Judith Smentkiewicz was on a ventilator with Covid-19 when her loved ones were told she'd likely spend another month in the ICU, where they gave her a 20 per cent
chance of survival. The family did some research on ivermectin's success. They pressed an ICU doctor to give it, and, on day 12 of infection, he did. Within 48 hours of a single dose,
Mrs Smentkiewicz had improved so much that she was moved out of critical care.
But doctors on the new unit declined to continue ivermectin even as the woman's condition declined. The drug is not approved for COVID; they told her family. The family went to court,
and the judge ordered the treatment resumed, and Mrs Smentkiewicz was released to a rehabilitation facility shortly. "It is a miracle from where she was." the family's attorney said.
NIH COVID-19 Treatment Guidelines Panel cannot draw definitive conclusions
on the clinical efficacy of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance
on the role of ivermectin in the treatment of COVID-19.
Ivermectin: Selected Clinical Data - February 11, 2021
Potential to save lives: An intensive care doctor argues for 'compassionate use' of ivermectin for Covid-19 - By Nathi Mdladla, 15 January 2021
Ivermectin, an antiparasitic (anti-helminthic) used for various parasitic diseases in humans and animals, has been extensively investigated in this drug.
The drug was not registered for human use in South Africa, but it is in many other countries, including the U.S., and "off-label" use is common.
As the Ivermectin effort during the pandemic reminded
Dr. Tess Lawrie of her work in South Africa, where there were known drugs that could help large numbers of people, yet they couldn't access such drugs,
she sprung into action during the Holiday Season, reviewing the work of the FLCCC and others and putting together what has become a compelling work.
Dr Lawrie states the data is clear that ivermectin markedly reduces the COVID-19 death rate. Hence, any debate about clinical trials at this point should be secondary to
figuring out how to accelerate emergency use as a complement to vaccines and other protective measures against the coronavirus.
At the conclusion of the January 14 BIRD conference, Dr. Lawrie delivered a monumental closing address that should be recorded among the most important speeches in the annals of medical history.
Dr. Lawrie spoke out at considerable personal risk, since her livelihood and career largely rely on the very agencies she targeted for criticism.
Dr. Lawrie began by endorsing the miraculous efficacy of IVM. Had ivermectin been employed in 2020 when medical colleagues around the world first alerted the authorities to its efficacy,
millions of lives could have been saved, and the pandemic with all its associated suffering and loss brought to a rapid and timely end.
Dr. Lawrie told the audience that the suppression of ivermectin was a signal that Pharma's pervasive corruption had turned a medical cartel against patients and against humanity.
For Dr. Lawrie and her conversion with Dr Andrew Hill and "
The assassination of Ivermectin and the death of millions".
Dr Jackie Stone describes on video how Zimbabwe's acceptance in January 2021 of ivermectin saved lives.
Not only does Dr Stone describe her success with ivermectin but how she believes it acts on SARS-CoV-2.
Ivermectin administration started in her clinic on 8th August. A colleague who ran a 22-bed hospital in an old-age care home was able to empty the hospital in six days,
despite five of the patients being classed as 'critical' at the outset. In Dr Stone's own clinic two critical patients also survived and were discharged with oxygen for use at home.
"One of them I really sent home for palliative care, with a very good nurse". A few days later she was astonished to be told that in spite of apparently poor blood chemistry -
including a D-dimer level of 10,000 - the patient felt well and was walking round the garden. "From 8th August until 24th December I didn't lose a patient and if you look at
our patient group, 26% of them [had oxygen saturations] of less than 80%", she said.
Her usual dosage is .2 grams per 5 Kg, but in cases of higher viral load she gives bigger dosage. She has found clients who misunderstand instructions and took a week's dosage at once
without any side effects. She uses tablets when available otherwise the liquid form. She also describes her experience catching SARS-Cov-2 and taking ivermectin.
Dr John Campbell looks at the best ivermectin meta analysis and examination of bias.
Belgian Virologist proposes a plan to eradicate Covid-19 in 6 weeks using Ivermectin.
Quoted is the analysis by Dr Tess Lawrie in the UK based on 15 randomised trials, including 4,000 patients. It reduces death by 83%, reducing the risk of deterioration by 53%.
As prophylaxis to frontline workers and others exposed to the virus, particularly in households, reduces the risk of infection by 88%. The suggested dosage is .2 mg per kg for prophylaxis,
then the second dose in 48 hours, then every two weeks. As to objections to the lack of an RDBPC, Dr Wathelet's counter-argument" "It would be foolish to wait for the slow and flawed
peer-review process in the context of a pandemic when lives are at stake".
Slovakia Becomes the First EU Nation to Formally Approve Ivermectin for Both Prophylaxis and Treatment for COVID-19 Patients - January 28, 2021.
The medicine will also be available at licensed prescription pharmacies.
Central American Nation of Belize Authorizes
Use of Ivermectin for COVID-19 - December 24, 2020. The move basically represents a sort of pragmatic survival as a Latin American developing nation seeks answers to the pandemic.
Macedonia Pharmacies to Supply with Ivermectin
for COVID-19 as MALMED Apparently Authorizes.
Portuguese doctors support Ivermectin
to treat early signs of Covid-19. Portuguese doctors may be divided over the use of anti-parasitic medication Ivermectin to treat the early stages of Covid-19,
but those that support it are adamant that it works.
Uttar Pradesh - which distributed free ivermectin for home care - had the second-lowest fatality rate in India at 0.26 per 100,000 residents in December. Only the state of Bihar, with 128 million residents, was lower, and it, too, recommends ivermectin.
But Uttar Pradesh did more than treat 300,000 mild cases at home through 2020; it also opted to use ivermectin to prevent infection. It seems a young health officer's COVID response teams had taken the drug and remained well - something prophylaxis studies support. U.P. then had contacts of COVID patients take it, with similar success. "Recognising the sense of urgency," Amit Mohan Prasad, a U.P. health official, wrote in a Dec. 30 article, "we decided to go ahead."
Still no luck with Ivermectin
Whether ivermectin, with a maximum targeted dose of 600 µg/kg, shortens symptom duration or prevents hospitalization among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) remains unknown.
The need and benefits of repurposing existing drugs and overcoming resistance
However there are as yet no peer reviewed randomized double-blind placebo-control (RDBPC) studies which are considered the "gold standard" of epidemiologic studies that are acceptable to Western medical bodies for repurposed drugs to cure Covid-19. One problem with RDBPC is their cost, which cost may be acceptable to a patented drug that could make its owners huge profits, but there are few volunteers to pay for an RDBPC for an existing drug to be used for treating a different or new disease where any laboratory can manufacture the drug.
It defies logic that a drug, ivermectin, that was used 3,7 billion times with its main side effect being the dying parasites it was treating causing side effects, considered a "safe" drug, should suddenly be "A concerning lack of safety data in the majority of studies" per Merck.
Many drugs that could work off-label can not and will not be used, and many lives lost because of this anomaly and others in our medical system.
Additionally, since so many patients suffer from the "long covid" effect where symptoms continue for an extended period, it would be surprising, given the anti-inflammatory and antiviral activity that it is later proven not just to combat the acute viral illness but also may be effective against the long covid.
People Died. The Establishment Played Games - Here's what it took, and how disgracefully long it took, for a simple COVID research project by Martin Makary MD, MPH, Editor-in-Chief, MedPage Today March 8, 2021.
"Our normal time and cycle for discovery and dissemination of information is way too freaking long. It's absurd, this idea of you put something in an abstract form, you submit it, then you sit back and relax and wait to hear back three months later, then the conference says, "Sure, you can present it next fall." Then you present it at the meeting, and then you submit it to a journal, then it goes into a queue, and a year and a half after the research discovery, the rest of the medical community learns about it in a peer-review publication. That's a disgrace, and it doesn't work during a health emergency."
Ivermectin has saved thousands of lives of Covid-19 sufferers worldwide. As an example of an intractable twentieth-century medical mindset, ivermectin was banned in South Africa, see below for the history of litigation. Authorities such as the South African Health Products Regulations Authority (Sahpra) reject new ideas without randomised, double-blind placebo-control (RDBPC) study, which takes money; the time delay will cost many thousands of lives. To quote, "Sahpra said there was no clinical evidence available for the use of Ivermectin in the management of Covid-19 infections." They have resisted its use or accepted its effectiveness without RDBPC evidence, and reports of its success in the real world are not evidence. Sahpra and other bodies will not accept the successful reports that many studies included were not peer-reviewed and meta-analyses are prone to confounding issues, plus many were in what could be termed third world countries where the resources for an RDBPC trial were limited.
"Meanwhile, Pfizer got their approval from studies done overseas, so it is hypocritical of our (USA) agencies of approving certain things that were done overseas and then not approving other things done overseas. See Dr Ryan Cole's presentation 16 minutes 30 Seconds in." Dr Cole also says that the cost in India is 2 cents a dose, although when compounded in America the cost is about $2 to $5 a dose.
However, with so much practical success with a low-cost drug that has such low side effects, its use should be encouraged, not scorned and denigrated.
For some reason, there seems to be a concentrated effort to knock down every low cost proposed Covid-19 relief.
Perhaps it is time for a faster, simpler authorisation system such as allowing registered repurposed drugs to be prescribed by registered medical professionals, even allowing health insurance funds to pay for the drugs.
Could there be any connection between promoting costly new drugs and rubbishing possibly effective patent expired old drugs?
Merck has issued a strongly worded official notification on 4 February 2021 that after extensive data review, "We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information."
Perhaps as per the Sydney Morning Herald on 13 July 2021 the fact that the US government has already agreed to pay Merck & Co. $US1.2 billion (A$1.6 billion) for the company's own experimental antiviral molnupiravir if it clears regulators is causing Merck to have 1,2 billion reasons to rubbish its own patent expired ivermectin.
"The Mectizan Donation Program provides treatments with the clear understanding that donated Mectizan will only be used for these two diseases (onchocerciasis and lymphatic filariasis) through mass drug distribution programs. Use of donated Mectizan for any other indication and at unauthorized doses is strictly prohibited and can be dangerous." Source.
This conflicts with the WHO saying "Unlike previous treatments, which had serious - sometimes fatal - side effects, ivermectin is safe and can be used on a wide scale."
Is someone not being completely honest? So if the patient is dying from Covid-19 and the doctor has Mectizan donated ivermectin for river blindness in his bag, the doctor dare not use the ivermectin. Interesting ethical medical advice!
FLCCC to Merck: The Data Shows Ivermectin's Strong Efficacy Against COVID-19. By FLCCC Feb 16, 2021 Updated Feb 18, 2021.
Dr Pierre Kory, President and Chief Medical Officer of the FLCCC, said that "The company's disregard for the most current medical evidence is an evidentiary indictment of their uncorroborated position. Merck's press release will cause governments, health authorities, medical providers, business leaders, and citizens to retreat from pursuing a medical agent that, according to our recent peer-reviewed and accepted publication to the highly regarded Frontiers in Pharmacology, has been proven to be an effective and globally available agent to prevent and treat every phase of COVID-19 disease."
"Merck shuts down Covid vaccine program MK-4482/MK-7110 after early trial data showed they failed to generate immune responses comparable to a natural infection or existing vaccines. By Riley Griffin, Bloomberg 25 Jan 2021"
Until January 2021 Merck was developing its own Covid vaccine. Could it be thought that falling mortality from the use of ivermectin would reduce demand for vaccine? Surely not! We are talking about 100s of thousands of lives v big profits.
It should be noted that Merck has put a lot of money into patent-protected molnupiravir (also known as EIDD-2801), described as last of the small molecule coronavirus hopes and wants to prioritise this drugs.
Antiviral drug 'Molnupiravir' blocks Covid-19 virus within 24 hours: Study "This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission. MK-4482/EIDD-2801 could be game-changing," said study author Richard Plemper from GSU.
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19.
The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, for $210 million and doses will be delivered through March 31, 2021. That is at a cost of $2,100 per dose.
Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. Additionally, the National Institutes of Health (NIH) recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression.
Authors note. That would appear to be about 420 times (42,000%) more costly than ivermectin which almost certainly does the same thing. No wonder there is pressure to denigrate ivermectin!!
"It is difficult to get a man to understand something when his salary depends upon his not understanding it."
- Upton Sinclair
Questioning the resistance to drug repurposing
Watch the SPARK Drug Repurposing Conference Tel Aviv University Oct 2020 webinar here.
Prof. Dan Peer, director of Spark and vice president of R&D at Tel Aviv University, urges governments across the world to create task forces focused on drug repurposing. "Spark's mission is to bring drugs as quickly and efficiently as possible to the clinic." "New therapeutics and diagnostics, repurposing of existing drugs and new entities for incurable diseases can save billions of dollars and many years in development by using a pool of thousands of FDA-approved drugs. We should be able to solve the problem of Covid-19 by overcoming bureaucratic red tape and financial barriers to new drug development."
"Of the 9,000 currently approved drugs that exist globally, the potential for overcoming Covid-19 certainly exists, " said the event organisers. "Instead of reinventing the wheel, we need to harness efforts to identify existing drugs that can treat Covid-19, select the safest ones, and validate their efficacy utilising rapid evaluation methods tailored to times of crisis."
The drugs to fight Covid-19 are already on the market.
Israeli experts say there's no need to reinvent the wheel, drug repurposing may be the fastest and cheapest way to treat people infected with the novel coronavirus. Peer and Rogosnitzky urge governments across the world to create task forces focused on drug repurposing.
Ivermectin Triple Therapy Protocol for COVID-19
Released to Australian GPs for Infected Elderly and Frontline Workers. "The three medications are on chemist shelves right now. GPs can email GP@CDD.com.au to obtain the dosing protocol and COVID-19 treatment information for their patients. Professor Borody continued: "GPs can legally prescribe the therapy today as an "off label" treatment according to Australian Guidelines - a standard practice in medicine. More than 60% of prescriptions in Australia are "off-label". It's not a new concept. It's happening every day to manage diseases and save lives."
January 20, 2021, Paul Sax, MD, a professor of medicine at Harvard
and clinical director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital in Boston, wrote in a blog post earlier this month in the New England Journal of Medicine Journal that ivermectin has more robust evidence for it than HCQ ever did. "But we're not quite yet at the 'practice changing' level," he writes. "Results from at least five randomised clinical trials are expected soon that might further inform the decision," Sax advises against two biases in considering ivermectin. First, one is assuming that because HCQ failed, (a questionable assumption)
other antiparasitic drugs will too.
The second bias to avoid, he says, is discounting studies done in low- and middle-income countries because "they weren't done in the right places."
"That's not just bias," he says. "It's also snobbery."
Bill and Melinda Gates Fund Global Ivermectin and Fluvoxamine Clinical Trial targeting Covid-19 titled the Together Covid-19 trial. Participating is Canada, Brazil, South Africa's University of Stellenbosch and sites in the USA.
When announced this trial drew cynical comments similar to - "Funding to discredit it or promote? We shall see." and "Will this involve another deliberately flawed and /or fraudulent study as for hydroxychloroquine?"
Comparing the results from two similar double-blind, randomized trials by Sheba (the 9th best hospital in the world) and in Cali, Colombia we get different conclusions from similar trials.
Link to pdf created from Prof Eli Schwartz pre-presentation video.
Among Adults With Mild COVID-19. A Randomised Clinical Trial JAMA. March 4, 2021. Findings: In this randomised clinical trial that included 476 patients, according to the authors, the duration of symptoms was not significantly different for patients who received a 5-day course of ivermectin compared with placebo. There was a reduction from 12 to 10 days duration for the ivermectin group, dismissed by the authors.
"The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand effects on other clinically relevant outcomes."
This trial showed a different result to the Sheba trial above. The differences in the trials were:
Sheba trial Ivermectin dosage 150-300 µg/kg/day; X 3 days, within 72 hours of molecular detection of Covid-19 with symptoms, 1 week if asymptomatic.
Cali, Colombia trial Ivermectin dosage 300 µg/kg of body weight per day for five days, within seven days of symptomatic, laboratory-confirmed Covid-19
Sheba average age 39.8 from 22 to 72 years, Cali average age 37, from 29 to 48 years, excluded if they were asymptomatic.
Sheba patients were in non-hospitalised, community-based, dedicated accommodation. Cali patients were at home or in the hospital.
Sheba patients were supplied ivermectin in capsules of 3mg. (produced by Super-Pharm), Tecnoquí provided Cali Ivermectin;micas SA in bottles of 0.6% solution for oral administration. Patients were asked to take the investigational product on an empty stomach, except on the first study day.
Sheba patients were evaluated by swab PCR on days 2, 4, 6, 8, 10,14. Cali patients were contacted by telephone by study staff on days 2 through 5, 8, 11, 15, and 21 for a structured interview. A study physician reviewed the medical records of hospitalised patients to obtain the information required by the protocol.
In the Sheba group, the outcome was a decrease from 90% positive in the control group at day 6 to 67.5% (25% decrease) in the ivermectin group with 48 patients per group.
In the Cali group, the median time to resolve symptoms was 10 days in the ivermectin group compared with 12 days in the placebo group. Although the Ivermectin group resolved symptoms 2 days sooner, this was dismissed "the duration of symptoms was not significantly different".
Possible reasons for differing conclusions.
There is no explanation why the Cali trial dismissed the two days less duration in symptoms. In effect, the trial proved that ivermectin reduced the duration of the illness! In the pragmatic PRINCIPLE trial duration of illness was significantly shorter in the 751 patients assigned to budesonide - by 2.6 days versus standard care. Median times to self-reported recovery were ten days. What reason was there to ignore a similar improvement in the Cali group as not significant?
In the Cali trial, patients were asked by phone about their symptoms and how they felt. This is subjective as patients may have expected to be sick for 21 days, and that may have influenced their answers, rather than objective answer, compared to the PCR tests in the Sheba trial. If there had been PCR tests, it might have disclosed a greater reduction in the duration.
The Cali patients were young, with the oldest being 48, while 24% of the Sheba patients were over 50.
The Cali patients took liquid ivermectin, while the Sheba patients took tablets more common in the West. It appears that Ivermectin has an unpleasant taste, and since the patients were unsupervised at home, this may have discouraged some patients from completing the dosage.
It may have no bearing on the conclusions. Still, many of the authors of the Cali trial in their Conflict of Interest Disclosures have received grants and fees for other work from Sanofi Pasteur, GlaxoSmithKline, Janssen, Merck Sharp & Dohme and Gilead outside the submitted work.
Articles Why You Should Not Use Ivermectin to Treat or Prevent COVID-19
Using any treatment for COVID-19 that's not approved or authorised by the FDA, unless part of a clinical trial, can cause serious harm. The FDA has received multiple reports of patients who have required medical support and been hospitalised after self-medicating with ivermectin intended for horses.
FDA has not approved ivermectin for use in treating or preventing COVID-19 in humans. Ivermectin tablets are approved at very specific doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an antiviral (a drug for treating viruses).
Taking large doses of this drug is dangerous and can cause serious harm.
If you have a prescription for ivermectin for an FDA-approved use, get it from a legitimate source and take it exactly as prescribed.
Never use medications intended for animals on yourself. Ivermectin preparations for animals are very different from those approved for humans. Many inactive ingredients found in animal products aren't evaluated for use in people. Or they are included in much greater quantity than those used in people. In some cases, we don't know how those inactive ingredients will affect how ivermectin is absorbed in the human body.
Merck say ", In accidental intoxication with, or significant exposure to, unknown quantities of veterinary formulations of ivermectin in humans, either by ingestion, inhalation, injection, or exposure to body surfaces, the following adverse effects have been reported most frequently: rash, edema, headache, dizziness, asthenia, nausea, vomiting, and diarrhea. Other adverse effects that have been reported include seizure, ataxia, dyspnea, abdominal pain, paresthesia, urticaria, and contact dermatitis."
Two Groups Review Evidence for Ivermectin Very Differently Recently, a large, multi-center based group of Canadian researchers Bartoszco of McMaster University, et al) conducted a living systematic review and network meta-analysis to investigate and compare the effects of possible repurposed drugs for prophylaxis on SARS-CoV-2. The UK-based group reviewed their systematic review on ivermectin, known as the British Ivermectin Recommendation Development (BIRD) COVID-19.
The Canadian group graded the evidence on ivermectin for prevention of COVID-19 infection as "very low certainty," while the recent BIRD group, which employed the gold standard guideline development tool-a DECIDE evidence to decision framework in adherence with the World Health Organization Handbook on Guideline Development, produced a "low certainty evidence".
The Ivermectin Story
Ivermectin, 'Wonder drug' from Japan: the human use perspective with Ivermectin history. The scientist who found the substance some 50 years ago in a bit of Japanese soil called it "astonishingly safe" in 2011 and a "wonder drug" in a class with penicillin and aspirin. Other scientists agree it has a stellar safety record.
10 February 2011. "Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin—originating solely from a single microorganism isolated at the Kitasato Institute, Tokyo, Japan from Japanese soil-has had an immeasurably beneficial impact in improving the lives and welfare of billions of people throughout the world. Originally introduced as a veterinary drug, it kills a wide range of internal and external parasites in commercial livestock and companion animals. It was quickly discovered to be ideal in combating two of the world's most devastating and disfiguring diseases, which have plagued the world's poor throughout the tropics for centuries. It is now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally. It has also been used to successfully overcome several other human diseases, and new uses for it are continually being found. This paper looks in depth at the events surrounding ivermectin's passage from being a huge success in Animal Health into its widespread use in humans. This development has led many to describe it as a "wonder" drug."
Obtaining and Ivermectin Dosages
Directory of Doctors Prescribing Effective mainly IVM and HCQ Outpatient COVID-19 Therapy. The general population will not have access to COVID-19 vaccines for several months. Even when available, the vaccines will not be 100% effective; people will continue to contract COVID-19 and require effective treatment of the disease. Currently available treatments (provided by the doctors listed in the directory below) will remain important to limit physical, emotional and economic suffering resulting from COVID-19.
Steps To Obtain COVID-19 Medication: Ivermectin and HCQ.
Click on the Contact A Physician button. Fill out the form and pay $90. The physician will call you typically within 24 to 48 hours. After your telemed appointment, the pharmacy will contact you to send the prescription to you for your payment information and mailing address. "We cannot simply 'send' prescriptions to another pharmacy; we know that it is highly likely that the prescription will not be filled at your local pharmacy, which is a waste of everyone's time. We are outside the insurance system specifically because the insurance system is blocking you from obtaining what you need for your good health." This link is provided here for anyone who finds it difficult to obtain ivermectin but where its usage is not forbidden by law.
Video of Dr Darrell DeMello about treating COVID-19 patients & Long Haulers in Mumbai, India with colchicine, ivermectin and anti-clotting agents. He suggests 12 mg two hours before and after for ivermectin to ensure maximum absorption.
Ivermectin Triple Therapy Protocol for COVID-19 Released to Australian GPs for Infected Elderly and Frontline Workers.
1. Ivermectin 2. Zinc 3. Doxycycline.
Ivermectin in South Africa
Potential to save lives: An intensive care doctor argues for 'compassionate use' of ivermectin for Covid-19 - 15 January 2021
These were the impactful and statistically significant results from the meta-analysis favouring ivermectin compared with a placebo. They showed:
Patients are dying in droves in the meantime due to a system that has been failing them before this pandemic and is being laid bare now.
Medicine professor slams SA Ivermectin sceptics; many experts aren't looking at the right data
- Faster viral clearance - an obvious marker of drug effect;
- Shorter hospital stay - a measure more relevant in resource-constrained environments;
- 48% higher rates of clinical recovery;
- An 83% increase in survival rates - the goal of most therapeutic interventions; and
- The drug was effective in all the clinical stages of the disease - prevention/prophylaxis->out-of-hospital treatment - and treatment of severe disease.
- It is in this context that it bewilders the mind why a drug like ivermectin should not be used for the management of Covid-19 patients for the benefit of its many phases of proven efficacy:
- Prophylaxis using the I-Mask Protocol to limit frontline staff infections - this can be extended to all frontline workers, including food industry staff, police, teachers, public transport drivers and hospitality industry workers. That way, we can have a reasonable continuation of essential services.
- It can be used to reduce or limit the need for hospital admissions and early outpatient treatment protocols like this one. We are already overburdened, and ivermectin holds clear evidence of benefit for out-of-hospital treatment;
- It can reduce hospital stay in very sick patients and improve mortality overall using protocols like the MATH+ Protocol - which allows discharging patients earlier and for clinicians to focus on the more severe cases with less therapeutic response.
Professor Colleen Aldous on Ivermectin:
We've got no vaccine that’s going to be 100% effective on the horizon just yet. It's going to take us at least a year in a vaccination programme. In the meantime, we will have a third wave of this disease, and we're going to get more variants coming through. So everything's going to get more complex. But we have a drug here that is available. It's cheap. It can be made in South Africa with compounding pharmacies. It's not under patent anymore. It could have a huge impact right at the beginning of the disease by preventing a measure of transmissibility and preventing people from getting sicker.
Ivermectin and Covid-19: SA drug regulator allows controlled, compassionate access
By Mark Heywood - 27 January 2021
Consider antiparasitic to avoid possible third Covid-19 wave, health minister urged 4 January 2021 Subrayan Naidoo said Shaik Emam had made a number of attempts to meet the health minister and the department of health to discuss the use of ivermectin to combat the transmission of the virus, without success. "Our client has video evidence which shows that the drug Ivermectin is yielding positive results in combating SARS-CoV-2 and has had no side effects on patients. Our client has reliably learnt that it will cost a total of R50m to manufacture the drug Ivermectin which will treat the population of SA."
Doctors may use ivermectin for Covid-19 in South Africa - Cape Times 3 Feb 2021 ZELDA VENTER
THE FIRST official step in the use of ivermectin as medicine for Covid-19 patients was given the green light by the Gauteng High Court, Pretoria, yesterday.
The court issued an order by agreement with the S.A. Health Products Regulations Authority (Sahpra) will enable doctors to start ivermectin treatment - which is not yet registered for human use within South Africa.
This court order will enable doctors to start ivermectin treatment concurrently with the submission of an Article 21 application in cases where the doctor deems urgent access to ivermectin as crucial for a patient.
According to the Medicines and Related Substances Control Act, an Article 21 application has to be submitted to Sahpra by medical practitioners who want to prescribe medicine that is not registered for human use within South Africa.
AfriForum, one of the parties in the urgent application for ivermectin's use, said this was a ground breaking breakthrough because doctors would not have to wait for approval of an Article 21 application before starting treatment.
It was also a huge victory as doctors could decide to proceed with treatment using their judgment.
Health products regulator 'did not buckle under pressure' over ivermectin Cape Times - 4 Feb 2021
Naseeba Kathrada, a Westville KZN doctor, said in an affidavit that as they were facing the ravages of the pandemic in their everyday work, they wanted the go-ahead from the court to legally use ivermectin as well a for their many patients who dearly wanted to use it.
She said the main application - still to be heard - was extremely urgent as it dealt with life and death matters.
The latest seven-day average of 482 deaths in the country due to Covid-19 proved urgency.
Kathrada said should ivermectin prove to be just 10% efficient in the long run, resulting in 48 lives being saved each day.
THE South African Health Products Regulatory Authority (Sahpra) has rejected the notion that it had buckled under pressure over granting access to ivermectin to the public.
Sahpra chief executive Dr Boitumelo Semete-Makokotlela denied giving in to public pressure after a court application by, among others, Afriforum.
On Tuesday, the North Gauteng High Court in Pretoria made an order, on agreement with Sahpra, that doctors can prescribe ivermectin even though the controversial drug is yet to be approved for human use. Doctors will now be able to start ivermectin treatment concurrently with submitting an Article 21 application to Sahpra in cases where urgent access to the drug is deemed crucial for a patient.
According to the Medicines and Related Substances Control Act, an Article 21 application has to be submitted to Sahpra by medical practitioners who want to prescribe medicines not registered for human use in South Africa.
"The court deliberations culminated in an order that reiterates the position that Sahpra communicated on January 27. In other words, Sahpra's programme of controlled compassionate use of ivermectin remains firmly in place," Semete-Makokotlela said.
SOUTH AFRICA - Ivermectin for Covid-19: Compound may be made up on prescription
The upshot of a settlement agreement made an order of court in four applications against the SA Health Products Regulatory Authority (Sahpra).
In terms of the agreement, the anti-parasitic drug can now be "compounded" and prescribed legally to treat specific patients.
Doctors no longer have to use the "compassionate use" programme, initiated by Sahpra earlier this year, in which doctors had to apply through the authority's Section 2 "compassionate use" programme (for unregistered medicines) for permission to use the drug to prevent and treat Covid-19.
According to the order signed off by Pretoria High Court judge Cassim Sardiwalla, Sahpra has to report back to the court every three months, detailing any developments in the use and availability of the drug. Sahpra is appealing this order.
It is believed the order came about after Sahpra approved the use of ivermectin in a cream to be used for skin conditions.
This approval meant the drug was now officially registered in SA.
The order states pharmacists and doctors are permitted to make up small batches of medicine containing ivermectin on prescription by a doctor and in small quantities.
General practitioner George Coetzee brought the court applications with AfriForum, the ACDP and Doctors for Life, a group of pharmacies and the "I Can Make a Difference" group of medical practitioners.
In terms of the order, Sahpra will contribute almost R2m to their legal fees. 07 April 2021.
A recent arrest at Durban's King Shaka International Airport involved a man found in possession of ivermectin, a drug lauded as a 'miracle treatment' for Covid-19. But the drug, banned from import by the local drug regulator, has not been proven safe or effective in treating or preventing the disease.
Crooks cash in on the Covid-19 pandemic 7 March 2021. Last month, a preliminary study conducted by the Soweto Clinical Trials Centre found five different tablet formulations of sourced ivermectin, none was Sahpra-registered. "Eighty per cent of the tablets tested in this study contained undeclared medical compounds that are unknown to the prescriber, with potential concerns for patient safety," it said. The study further found that all the tablets labelled as having been manufactured in India contained at least one undeclared active pharmaceutical ingredient, including antihistamines, blood thinners and hypnotics.
In Vitro Ivermectin reports
The objection that the "concentration of ivermectin needed to inhibit SARS-Cov-2 replication in vitro is a level that cannot be reached in the plasma in vivo in people, Belgium Dr Wathelet answers "Ivermectin is highly lipid-soluble and consequently tissue levels are higher than plasma levels. Ivermectin has blood spectrum anti-viral activities and anti-inflammatory activities."
7 August 2020. The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Dr Thomas Borody; Ivermectin treatment is a 'real killer of coronavirus'
Professor Borody is most famous for his ground breaking work developing the triple antibiotic therapy cure for peptic ulcers in 1987, which has saved hundreds of thousands of lives, and the Australian health system more than $10 billion in medical care and operations.
Professor Borody founded the Centre for Digestive Diseases (CDD) in 1984 after a distinguished career with leading hospitals, including St Vincent's in Sydney and the Mayo Clinic in the USA.
The Ivermectin connection was first discovered by Dr Kylie Wagstaff's team at Monash University in April 2020.
June 2020 - Science Direct report here that ivermectin, an FDA-approved antiparasitic previously shown to have broad-spectrum antiviral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post-infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin, therefore, warrants further investigation for possible benefits in humans.
D, L-lysine acetylsalicylate + glycine Impairs Coronavirus Replication Here we show that D, L-lysine acetylsalicylate + glycine sold as "Aspirin i.v. 500mg®" (LASAG), which is an approved drug inter alia in the treatment of acute pain, migraine and fever, impairs propagation of different CoV including the highly-pathogenic MERS-CoV in vitro. We demonstrate that the LASAG-dependent impact on virus-induced NF-?B activity coincides with (i) reduced viral titers, (ii) decreased viral protein accumulation and viral RNA synthesis and (iii) impaired formation of viral replication transcription complexes.
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE
The information, including but not limited to text, graphics, images, videos, and other material contained on this website, are for informational and educational purposes only. No material on this site is intended to substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website. The author of this website has no connection, either paid or voluntary, with any organisation mentioned. From reading the literature referred to, admittedly personally believes that ivermectin could make a difference to the progress of the SARS-CoV-2 disease.